Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients
✍ Scribed by Marc Wirden; Anne Genevieve Marcelin; Anne Simon; Myriam Kirstetter; Roland Tubiana; Marc-Antoine Valantin; Luc Paris; Manuela Bonmarchand; Francoise Conan; Laurence Kalkias; Christine Katlama; Vincent Calvez
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 66 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The aim of the study was to describe the pattern of resistance mutations in human immunodeficiency virus type 1 (HIV‐1) infected patients experiencing their first protease inhibitor (PI) failure on nelfinavir (NFV)‐containing therapy. Earlier PI‐naïve patients (n = 172) with NFV‐contain
## Abstract The HIV‐1 protease L76V mutation has been described recently as conferring high‐level resistance to lopinavir/ritonavir (LPV/r). The aim was to identify the factors and particularly protease mutations associated with the presence of L76V in treatment‐experienced patients infected with H
## Abstract Recent studies have highlighted the need of investigating the in vivo role of ribonuclease H (RNase H) in nucleoside reverse transcriptase inhibitors (NRTIs) resistance. The prevalence of RNase H mutations in naive and in NRTI pre‐treated patients in regimen failure were compared and so
Clinical and in vitro studies have suggested that nelfinavir (NFV)-containing regimens may not preclude the use of other protease inhibitors (PIs) in treatment sequencing. We have studied the prevalence of 30N mutation in a human immunodeficiency virus-1 (HIV-1)-infected cohort and the virological r
## Abstract Evaluation of resistance pattern in patients with chronic hepatitis B. Retrospective study of hepatitis B virus (HBV) resistance mutations in patients found viraemic after first‐line treatment. HBV viral load was determined by a real‐time polymerase chain reaction and the substitutions